Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Chemomab Therapeutics
Ltd. (the “Company”) hereby furnishes under this Report of Foreign Private Issuer on Form 6-K (the “Form 6-K”)
a press release, dated November 19, 2026, titled “Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides
Corporate Update” as Exhibit 99.1 to this Form 6-K.
Exhibit 99.1 to this Form
6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form S-8 (File No. 333-259489
and No. 333-266868).
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1

Chemomab
Therapeutics Announces Third Quarter 2026 Financial Results and
Provides Corporate Update
Proposed
merger with Scipher Medicine with plans to assess nebokitug in a Phase 2 precision medicine trial in
rheumatoid arthritis (RA) continues
to advance, with closing expected in the first quarter of 2027
S-4 registration
statement declared effective by SEC -- Special Meeting of Chemomab shareholders to vote on the
proposed merger is scheduled for December
4, 2026
TEL AVIV, Israel, November 19, 2026 -- Chemomab Therapeutics
Ltd. (Nasdaq: CMMB) (“Chemomab”), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic
diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2026, and provided
a corporate update.
Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, said,
“We continue to make meaningful progress toward completing our proposed merger with Scipher Medicine Corporation (“Scipher”).
The SEC’s declaration of effectiveness of the Form S-4 registration statement represents an important milestone and we look forward
to our shareholder meeting scheduled for December 4, 2026. Subject to shareholder approval and the satisfaction of the remaining closing
conditions, we anticipate completing the transaction in the first quarter of 2027.”
Dr. Mor continued, “With our colleagues at Scipher, we completed
a Type B Pre-Investigational New Drug (Pre-IND) interaction with the U.S. Food and Drug Administration (FDA) regarding the planned Phase
2 trial of nebokitug in RA. The FDA provided feedback that was generally consistent with our development assumptions as we advance toward
a planned IND submission.”
Dr. Mor added, “We believe this proposed merger provides our
shareholders an opportunity to potentially realize value through the clinical advancement of nebokitug in RA, which currently represents
a worldwide market estimated at approximately $24 billion annually with substantial unmet need, as well as through Scipher’s revenue-generating
precision medicine business and its biopharma partnerships. We continue to work closely with our colleagues at Scipher to advance toward
completion of the proposed transaction and facilitate initiation of the Phase 2 trial in RA, marking a new phase in the development of
nebokitug and our anti-CCL24 platform.”
The proposed merger is expected to create an immunology precision medicine
company that leverages Scipher’s precision medicine capabilities, including SPECTRA™, Scipher’s AI-powered network medicine
platform, its growing portfolio of precision medicine assays for predicting treatment response, including PrismRA® and PrismTcell™,
and its biopharma partnerships, along with Chemomab’s clinical-stage anti-CCL24 antibody nebokitug. As previously reported,
SPECTRA identified nebokitug as the highest ranked clinical-stage candidate for RA. Assuming the closing of the proposed merger in the
first quarter of 2027, the combined company plans to initiate a Phase 2 trial of nebokitug in RA in the first half of 2027, with topline
results projected in the first half of 2028.
Third Quarter 2026 and Recent Highlights:
| · | Form S-4 Registration Statement Declared Effective by SEC. On October 30, 2026, the U.S.
Securities and Exchange Commission (“SEC”) declared effective the Registration Statement on Form S-4 (as amended) filed by
Chemomab and Snowdrift Parent Corporation in connection with the proposed business combination between Chemomab and Scipher (the “Registration
Statement”). The definitive proxy statement/prospectus for the special meeting of Chemomab’s shareholders in connection with
the proposed merger, as supplemented on November 10, 2026 (the “Proxy Statement”), is also available. Chemomab shareholders
of record as of October 29, 2026 will have the opportunity to approve the proposed business combination at a special meeting of Chemomab
shareholders scheduled for Friday, December 4, 2026, at 3:00 pm Israel time (8:00 am Eastern Time). If the proposed business combination
is approved, it is expected to close in the first quarter of 2027, subject to the expiration of the waiting periods required under Israeli
law in connection with the domestication merger (including at least 30 days following shareholder approval), as well as satisfaction of
customary closing conditions. |
| · | Completed Nebokitug Pre-IND Interaction with FDA. In September 2026, Chemomab and Scipher
completed a Type B Pre-IND interaction with the FDA, receiving written feedback consistent with their development plans for the proposed
Phase 2 trial of nebokitug in moderate-to-severe RA patients. The companies are advancing preparations for the planned IND submission. |
| · | Entered into Definitive Merger Agreement with Scipher. On July 8, 2026, Chemomab announced
that it had entered into a definitive merger agreement (the “Merger Agreement”) with Scipher, pursuant to which the companies
will combine in an all-stock transaction (the “Merger”). Under the terms of the Merger Agreement, pre-merger Chemomab shareholders
and holders of equity awards are expected to own approximately 32% of the combined company, with Scipher convertible notes holders owning
approximately 68%, in each case on a fully diluted, as-converted basis, prior to giving effect to the concurrent private placement financing
and subject to adjustment as set forth in the Merger Agreement. The combined company is valued at $150 million prior to a concurrent $30
million private placement financing and is expected to have sufficient cash to fund operations through the readout of the nebokitug Phase
2 RA trial. The private placement is being led by a syndicate of current Scipher investors, including Northpond Ventures, with participation
from Khosla Ventures, Blue Owl Healthcare Opportunities, funds managed by Neuberger, and other leading investors, and includes 100% warrant
coverage, with the warrants having an exercise price based on a $75 million valuation. In addition, immediately following the closing,
pre-merger Chemomab shareholders and holders of vested equity awards will receive contingent value rights (CVRs), providing the opportunity
to receive potential payments of $10 million upon U.S. Food and Drug Administration approval of nebokitug for any indication and $40 million
upon the earlier of the initiation of a Phase 3 clinical trial of nebokitug in primary sclerosing cholangitis (PSC) or a disposition of
nebokitug in PSC, payable in cash, shares of the combined company’s common stock or a combination thereof, at the combined company’s
election, and in each case subject to the terms and conditions of the CVR agreement. Upon completion of the Merger, the combined company
is expected to operate as Scipher Medicine Corporation and trade on the Nasdaq Capital Market under the ticker symbol “SCIP.”
The combined company plans to initially focus on advancing nebokitug, a potential first-in-class clinical stage anti-CCL24 antibody, into
a Phase 2 clinical trial for the treatment of RA, with topline results projected in the first half of 2028. Following the closing, Dr.
Reginald Seeto will serve as Chief Executive Officer of the combined company, and Chemomab co-founder and Chief Executive Officer Dr.
Adi Mor will join the combined company’s Board of Directors. |
The Registration Statement and
the Proxy Statement are available at www.sec.gov and also at the Investors page on the Chemomab website at www.chemomab.com.
Chemomab shareholders are encouraged to vote their shares as soon as possible so they can be tabulated prior to the Special Meeting.
Third Quarter 2026 Financial Highlights:
| · | Cash Position and Liquidity: Cash, cash equivalents and short-term bank deposits were $4.7 million as of September 30,
2026, compared to $6.7 million as of June 30, 2026. On November 3, 2026, Chemomab sold 932,203 ADSs to Scipher at a price of $1.18 per
ADS through its existing At-the-Market (ATM) financing program, for gross proceeds of approximately $1.1 million. Chemomab expects that
this financing, together with its existing cash, will fund its operations through the first quarter of 2027. Scipher purchased the ADSs
pursuant to the Merger Agreement, under which Scipher agreed to provide up to $1.1 million of financing if Chemomab determined that it
required additional financing prior to closing. Scipher funded the purchase through the issuance of additional convertible notes to existing
Scipher investors, separate from their private placement financing commitments. The ADSs purchased by Scipher are being held by Scipher
for the benefit of its noteholders and are included in the Chemomab share count for purposes of the ownership allocation under the Merger
Agreement, and the purchase of ADSs by Scipher does not change the agreed 32%/68% ownership allocation between Chemomab and Scipher securityholders. |
| · | Research and Development (R&D) Expenses: R&D expenses were $3.7 million for the third quarter of 2026, compared to
$1.0 million for the third quarter of 2025. The increase in R&D expenses was primarily attributable to the recognition of approximately
$2.9 million of manufacturing costs that were prepaid during 2024 and 2025 and recognized as expenses in the third quarter of 2026. |
| · | General and Administrative (G&A) Expenses: G&A expenses were
$1.4 million for the third quarter of 2026, compared to $0.9 million for the third quarter of 2025. The increase in G&A expenses was
primarily attributable to costs associated with the proposed Merger. |
| · | Net Loss: Net loss was $5.1 million, or a net loss of less than $0.01
per basic and diluted ordinary share, for the third quarter of 2026, compared to a net loss of $1.7 million, or a net loss of less than
$0.01 per basic and diluted ordinary share, for the third quarter of 2025. The weighted average number of ordinary shares outstanding,
basic and diluted, was 644,367,295 (equal to approximately 8,054,591 ADSs) in the third quarter of 2026. |
| · | Number of Issued and Outstanding Shares: As of September 30, 2026,
Chemomab had 643,916,360 issued and outstanding shares (equal to 8,048,955 ADSs) compared to 575,381,320 (equal to 7,192,266 ADSs) as
of December 31, 2025. On November 3, 2026, following the issuance of shares to Scipher, the company had 719,107,400 issued and outstanding
shares (equal to 8,988,848 ADSs). |
About the Proposed Transaction
Under the terms of the Merger
Agreement, as of the closing and immediately prior to a proposed private placement financing, and subject to the assumptions and adjustments
set forth in the Merger Agreement, the pre-merger Chemomab shareholders (which includes Scipher as a holder of the ADSs purchased pursuant
to the ATM program) and holders of equity awards are expected to own approximately 32% of the combined company, and the pre-merger Scipher
convertible notes holders led by Northpond Ventures, with participation from Khosla Ventures and Blue Owl Healthcare Opportunities, and
other leading investors are expected to own approximately 68% of the combined company, each on a fully-diluted, as-converted basis and
prior to giving effect to the concurrent private placement financing. In addition, pre-merger Chemomab shareholders and vested equity
awards holders are expected to receive contingent value rights, or CVRs, providing the opportunity to receive additional value upon the
achievement of certain specified milestones related to nebokitug, subject to the terms and conditions of the CVR agreement. The transaction
has received unanimous approval from the boards of directors of both companies and is expected to close in the first quarter of 2027,
subject to certain closing conditions, including, among other things, approval by the shareholders of Chemomab, the redomiciling of Chemomab
to the United States, and the satisfaction of other customary closing conditions. In connection with the companies’ entry into the
Merger Agreement, certain officers, directors and shareholders of Chemomab who held approximately 20% of the voting power of Chemomab
have entered into support agreements, pursuant to which they have agreed to vote their share capital of Chemomab covered by such agreements
in favor of approval of the Merger Agreement and the transaction.
Additional information about
the proposed business combination is set forth in the Registration Statement and the Proxy Statement. Investors and security holders are
urged to read those materials.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements in this press
release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal
securities laws, including for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express or implied statements regarding the structure, timing and completion
of the proposed merger; the parties’ ability to consummate the proposed transaction and the related proposed private placement financing;
Chemomab’s expected cash runway and the combined company’s expected cash runway; the combined company’s expected listing
on Nasdaq and ticker symbol after closing of the proposed merger; expectations regarding the ownership structure of the combined company;
the future operations of the combined company; the expected issuance of the CVRs and the contingent payments or consideration contemplated
by the CVRs; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of
any product candidates of the combined company; anticipated clinical drug development activities and related timelines, including the
planned IND submission and the expected timing for trial initiation, data and other clinical results; the potential size of the market
opportunity for RA and other statements that are not historical fact. Any forward-looking statements in this release are based on management’s
current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and
assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking
statements. There can be no assurance that future developments affecting the combined company will be those that have been anticipated.
These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the combined company’s control)
or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the conditions to the closing
of the merger are not satisfied, including the failure to timely obtain shareholder approval for the transaction, if at all; uncertainties
as to the timing of the consummation of the merger and the ability of each of Chemomab and Scipher to consummate the merger; risks related
to Chemomab’s ability to manage its operating expenses and its expenses associated with the merger pending closing; risks related
to Chemomab’s limited cash resources and the sufficiency of its cash runway; the risk that the FDA does not accept an IND for, or
does not agree with the design of, the planned Phase 2 trial of nebokitug in RA, or that the timing of the IND submission, trial initiation
or data readout is delayed; the dilutive effect of additional issuances of Chemomab’s ADSs, including under its at-the-market facility;
risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to
consummate the merger; the risk that as a result of adjustments to the exchange ratio, Chemomab shareholders and equity awards holders,
and Scipher convertible notes holders could own more or less of the combined company than is currently anticipated; risks related to the
market price of Chemomab’s ADSs relative to the value suggested by the exchange ratio; unexpected costs, charges or expenses resulting
from the transaction; the uncertainties associated with Chemomab’s and Scipher’s product candidates, as well as risks associated
with the clinical development and regulatory approval of such product candidates, including potential delays in the commencement, enrollment
and completion of clinical trials; risks related to the inability of the combined company to obtain sufficient additional capital to continue
to advance these product candidates and its preclinical programs; the risk that the milestones under the CVRs are not achieved and no
payments are made thereunder; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that
may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed
and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market;
risks associated with the possible failure to realize certain anticipated benefits of the merger, including with respect to future financial
and operating results; the risk that the related proposed private placement financing is not consummated or is not consummated on the
terms and in the amounts currently anticipated; the risk of potential adverse reactions or changes to relationships with employees, suppliers
or other business relationships or parties resulting from the announcement or completion of the proposed transaction; and those uncertainties
and factors described under the heading “Risk Factors” in the Proxy Statement and in Chemomab’s Annual Report on Form
20-F for the year ended December 31, 2025 and Report on Form 6-K furnished to the SEC on August 19, 2026 containing interim financial
information for the quarter ended June 30, 2026, and Chemomab’s other filings from time to time with the SEC. Nothing in this press
release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking
statements in this press release, which speak only as of the date hereof and are qualified in their entirety by reference to the cautionary
statements herein. Chemomab and Scipher do not undertake or accept any duty to make any updates or revisions to any forward-looking statements,
except as required by applicable law.
NO OFFER OR SOLICITATION
This communication is not intended
to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed
transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe
for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities
in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the
requirements of the Securities Act of 1933, as amended, or an exemption therefrom.
NEITHER THE SEC NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.
IMPORTANT ADDITIONAL INFORMATION
ABOUT THE PROPOSED TRANSACTION
This communication is not a substitute
for any other document that Chemomab has filed or may file with the SEC in connection with the proposed transaction. In connection with
the proposed business combination, Chemomab and Snowdrift Parent Corporation have filed the Registration Statement, which was declared
effective by the SEC on October 30, 2026 and contains the Proxy Statement, and Chemomab filed a supplement to the Proxy Statement dated
November 10, 2026. CHEMOMAB URGES INVESTORS AND SHAREHOLDERS TO READ THE REGISTRATION STATEMENT, INCLUDING THE PROXY STATEMENT CONTAINED
THEREIN, AS SUPPLEMENTED, AND ANY OTHER RELEVANT DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS
TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT CHEMOMAB, SCIPHER AND THE OTHER PARTIES
TO THE MERGER AGREEMENT, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders may obtain free copies of the Registration
Statement and other documents filed by Chemomab with the SEC through the website maintained by the SEC at www.sec.gov. In addition, investors
and shareholders should note that Chemomab communicates with investors and the public using its website (www.chemomab.com) and the investor
media website (https://chemomab.com/investors-media) where anyone will be able to obtain free copies of the Registration Statement
and included Proxy Statement and other documents filed by Chemomab with the SEC, and shareholders are urged to read the Registration Statement
and the included Proxy Statement and the other relevant materials before making any voting or investment decision with respect to the
proposed transaction. The documents filed by Chemomab with the SEC also may be obtained free of charge upon written request to: Chemomab
Therapeutics Ltd., 121-123 Menachem Begin Road, 30th floor, Tel Aviv 6701203, Israel.
PARTICIPANTS IN THE SOLICITATION
Chemomab, Scipher and their respective
directors and executive officers may be deemed to be participants in the solicitation of proxies from Chemomab’s shareholders in
connection with the proposed transaction. Information about Chemomab’s and Scipher’s directors and executive officers, including
a description of their direct or indirect interests, by security holdings or otherwise, in Chemomab and Scipher and the proposed transaction,
is included in the Registration Statement and included Proxy Statement relating to the proposed transaction. These documents can be obtained
free of charge from the sources indicated above.
About Chemomab Therapeutics
Chemomab is a clinical -stage
biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need. Based on the unique role of
the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a potential first-in-class dual activity
monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug
has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and
life-threatening immune-fibrotic diseases. Chemomab has reported positive results from five clinical trials of nebokitug, including the
Phase 2 SPRING trial in patients with primary sclerosing cholangitis. For more information, visit: chemomab.com.
Contacts:
Media & Investors:
Chemomab Therapeutics
Barbara Lindheim
Consulting Vice President
Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
Chemomab Therapeutics Ltd.
and its subsidiaries
Interim Condensed Consolidated
Balance Sheets (Unaudited)
In USD thousands (except for share amounts)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Assets | |
| | | |
| | |
| | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Cash and cash equivalents | |
| 4,653 | | |
| 7,564 | |
| Short term bank deposits | |
| - | | |
| 2,802 | |
| Other receivables and prepaid expenses | |
| 576 | | |
| 3,059 | |
| | |
| | | |
| | |
| Total current assets | |
| 5,229 | | |
| 13,425 | |
| | |
| | | |
| | |
| Non-current assets | |
| | | |
| | |
| Long term prepaid expenses | |
| 80 | | |
| 211 | |
| Property and equipment, net | |
| 148 | | |
| 176 | |
| Total non-current assets | |
| 228 | | |
| 387 | |
| | |
| | | |
| | |
| Total assets | |
| 5,457 | | |
| 13,812 | |
| | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Trade payables | |
| 211 | | |
| 485 | |
| Accrued expenses | |
| 680 | | |
| 337 | |
| Employee and related expenses | |
| 878 | | |
| 656 | |
| | |
| | | |
| | |
| Total current liabilities | |
| 1,769 | | |
| 1,478 | |
| | |
| | | |
| | |
| | |
| | | |
| | |
| Commitments and contingent liabilities | |
| | | |
| | |
| | |
| | | |
| | |
| Total liabilities | |
| 1,769 | | |
| 1,478 | |
| | |
| | | |
| | |
| Shareholders' equity (*) | |
| | | |
| | |
| | |
| | | |
| | |
| Ordinary shares no par value - Authorized: 4,650,000,000 shares as of September 30, 2026 and December 31, 2025; issued and outstanding: 643,916,360 Ordinary shares as of September 30, 2026 and 575,381,320 Ordinary shares as of December 31, 2025. | |
| - | | |
| - | |
| | |
| | | |
| | |
| Additional paid in capital | |
| 124,307 | | |
| 123,952 | |
| Accumulated deficit | |
| (120,619 | ) | |
| (111,618 | ) |
| | |
| | | |
| | |
| Total shareholders’ equity | |
| 3,688 | | |
| 12,334 | |
| Total liabilities and shareholders’ equity | |
| 5,457 | | |
| 13,812 | |
(*) 1 American Depositary Share (ADS) represents 80 Ordinary Shares.
Chemomab Therapeutics Ltd.
and its subsidiaries
Interim Condensed Consolidated
Statements of Operations (Unaudited)
In USD thousands (except for share and per share amounts)
| | |
Three Months | | |
Three Months | | |
Nine months | | |
Nine months | |
| | |
Ended | | |
Ended | | |
Ended | | |
Ended | |
| | |
September 30, | | |
September 30, | | |
September 30, | | |
September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Operating expenses | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development | |
| 3,718 | | |
| 960 | | |
| 5,785 | | |
| 4,740 | |
| | |
| | | |
| | | |
| | | |
| | |
| General and administrative | |
| 1,373 | | |
| 884 | | |
| 3,397 | | |
| 2,853 | |
| | |
| | | |
| | | |
| | | |
| | |
| Total operating expenses | |
| 5,091 | | |
| 1,844 | | |
| 9,182 | | |
| 7,593 | |
| | |
| | | |
| | | |
| | | |
| | |
| Financing income, net | |
| 28 | | |
| 102 | | |
| 181 | | |
| 471 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss before taxes | |
| 5,063 | | |
| 1,742 | | |
| 9,001 | | |
| 7,122 | |
| | |
| | | |
| | | |
| | | |
| | |
| Taxes on income | |
| - | | |
| - | | |
| - | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Net loss for the period | |
| 5,063 | | |
| 1,742 | | |
| 9,001 | | |
| 7,122 | |
| Basic and diluted loss per Ordinary Share (*) | |
| 0.008 | | |
| 0.004 | | |
| 0.014 | | |
| 0.015 | |
| Weighted average number of Ordinary Shares outstanding, basic, and diluted (*) | |
| 644,367,295 | | |
| 494,338,497 | | |
| 641,175,985 | | |
| 471,436,609 | |